Masimo Co. (MASI) CEO Joe E. Kiani Sells 126,927 Shares
Masimo Co. (NASDAQ:MASI) CEO Joe E. Kiani sold 126,927 shares of Masimo stock in a transaction dated Friday, August 31st. The stock was sold at an average price of $117.85, for a total value of $14,958,346.95. Following the sale, the chief executive officer now owns 236,061 shares in the company, valued at approximately $27,819,788.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of NASDAQ MASI traded up $2.21 during midday trading on Tuesday, reaching $120.10. 470,700 shares of the company were exchanged, compared to its average volume of 528,512. Masimo Co. has a 1 year low of $80.69 and a 1 year high of $120.45. The firm has a market cap of $6.10 billion, a P/E ratio of 49.04, a P/E/G ratio of 2.75 and a beta of 1.02.
Masimo (NASDAQ:MASI) last released its quarterly earnings results on Wednesday, August 1st. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.71 by $0.02. Masimo had a return on equity of 21.49% and a net margin of 15.30%. The firm had revenue of $211.62 million for the quarter, compared to analyst estimates of $207.85 million. During the same quarter last year, the company posted $0.83 earnings per share. The business’s revenue was up 10.0% on a year-over-year basis. equities analysts forecast that Masimo Co. will post 2.9 EPS for the current year.
A number of analysts have recently commented on the company. Stifel Nicolaus lifted their target price on Masimo from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, August 2nd. BidaskClub upgraded Masimo from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 17th. ValuEngine upgraded Masimo from a “hold” rating to a “buy” rating in a research report on Monday, May 7th. Finally, Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $110.00 target price on the stock in a research report on Tuesday, July 3rd. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $102.60.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Further Reading: What does EPS mean?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.